Spotlight on Neurology

Credits: 0.50 CME / CNE
Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression
Richard Isaacson, MD
AcademicCME

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD
  2. Implement shared decision making with the multidisciplinary team and patients/caregivers to develop individualized treatment plans and referral to clinical studies to advance treatment and improve the quality of life for patients with AD

Activity Description

In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern day. Emerging therapies for the treatment and management of Alzheimer’s disease will also be assessed. Through completing this educational activity, learners will be better acquainted with emerging and emerged clinical trial data as it relates to AD care.

Statement of Educational Need

Health care team members need to be up-to-date on the most current strategies to delay disease progression in Alzheimer’s patients.

Agenda

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Marc E. Agronin, MD

Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Marc E. Agronin, MD
Consultant/Advisor: Eli Lilly and Company
Speaker's Bureau: Allergan

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Neurology Presentations

0.50 CME / CNE
Postgraduate Institute for Medicine
Treatment Decision Making and Achieving Therapeutic Goals in Multiple Sclerosis: Individual and Systems-Level Advances: Identifying Treatment Goals and Personalizing Therapy

Treatment Decision Making and Achieving Therapeutic Goals in Multiple Sclerosis: Individual and Systems-Level Advances: Identifying Treatment Goals and Personalizing Therapy

Start

Faculty

Edward Fox, MD, PhD
Clinical Associate Professor
Department of Neurology
University of Texas Dell Medical School
Austin, TX

Director, Multiple Sclerosis Clinic
Central Texas Neurology Consultants
Round Rock, TX


Lori Mayer, DNP, MSN, RN, MSCN
Director, Medical Research, MS Clinic of Central Texas
Central Texas Neurology Consultants
Round Rock, TX


Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and CMEology

    

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: September 12, 2017
Expires: September 12, 2018
30 minutes to complete

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

Activity Description

In this activity, experts in multiple sclerosis will discuss the identification of treatment goals, team-based goal setting, and treatment strategies.

Statement of Educational Need

Although MS care teams strive to control patients’ disease progression and symptoms, substantial gaps remain. For example, disparities were found between healthcare providers and patients when asked about frequency and perceived reasons for poor treatment adherence. The gap in goal achievement has far-reaching ramifications, not only for patient care, but also for human and economic costs at a systems level.

Goals (Purpose) of Program

Healthcare providers who complete this activity should be able to identify and discuss patients’ treatment goals and recommend optimal treatment strategies for patients with MS.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients’ current needs regarding MS education, realistic goal-setting, and understanding about adherence behaviors in MS management
  • Apply best practices to the successful implementation of interventions at the individual and systems levels

Target Audience

This certified activity is designed to address the educational needs of neurologists, neurology advanced practice clinicians, and other healthcare providers who care for patients with multiple sclerosis.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, the certificate will be made available immediately.

Media

Internet activity

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty have disclosed the following:
Edward Fox, MD, PhD
Consulting Fees:  Acorda Therapeutics, Bayer, Biogen, Inc., EMD Serono, Genentech, Genzyme, Novartis, Teva Pharmaceutical Industries, TG Therapeutics, Inc.; Contracted Research: Acorda Therapeutics, Biogen, Inc., Chugai Pharma USA, Inc., EMD Serono, Genentech, Novartis, Ono Pharma USA, Inc., Teva Pharmaceutical Industries, TG Therapeutics, Inc.

Lori Mayer, DNP, MSN, RN, MSCN
Consulting Fees (e.g. advisory boards):  Biogen, Inc., EMD Serono, Genentech, Novartis, Sanofi Genzyme; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g. speakers’ bureaus): Biogen, Inc., EMD Serono, Novartis, Sanofi Genzyme.

The following CMEology planners and managers, Rob Lowney, Dannielle McGuire, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please contact Postgraduate Institute for Medicine at: (303) 799-1930 or inquiries@pimed.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Postgraduate Institute for Medicine
Treatment Decision Making and Achieving Therapeutic Goals in Multiple Sclerosis: Individual and Systems-Level Advances: Evaluation and Management of Suboptimal Treatment Response

Treatment Decision Making and Achieving Therapeutic Goals in Multiple Sclerosis: Individual and Systems-Level Advances: Evaluation and Management of Suboptimal Treatment Response

Start

Faculty

Edward Fox, MD, PhD
Clinical Associate Professor
Department of Neurology
University of Texas Dell Medical School
Austin, TX

Director, Multiple Sclerosis Clinic
Central Texas Neurology Consultants
Round Rock, TX


Lori Mayer, DNP, MSN, RN, MSCN
Director, Medical Research, MS Clinic of Central Texas
Central Texas Neurology Consultants
Round Rock, TX


Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and CMEology

    

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: September 12, 2017
Expires: September 12, 2018
30 minutes to complete

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

Activity Description

In this activity, experts in multiple sclerosis will discuss the management of suboptimal response to therapy in patients with MS, including the use of care coordination and the application of systems-based change and interventions.

Statement of Educational Need

Since the advent of the first treatment for relapsing-remitting multiple sclerosis more than 2 decades ago, considerable changes have altered management approaches. In recent decades, the goals of treatment for MS have generally shifted from reducing the frequency and severity of relapses and delaying progression to preventing new or enhancing lesions on magnetic resonance imaging and reducing brain atrophy. Healthcare providers increasingly rely on coordination of care and systems-based strategies to manage MS in patients who have a suboptimal response to therapy.

Goals (Purpose) of Program

Healthcare providers who complete this activity should be able to coordinate care and work within healthcare systems to effectively manage treatment of patients with MS, particularly those with a suboptimal response to disease-modifying therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients for whom treatment goals may need updating or revision
  • Apply current recommendations for target outcomes in MS management to the evaluation of suboptimal response in appropriate patients

Target Audience

This certified activity is designed to address the educational needs of neurologists, neurology advanced practice clinicians, and other healthcare providers who care for patients with multiple sclerosis.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, the certificate will be made available immediately.

Media

Internet activity

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty have disclosed the following:
Edward Fox, MD, PhD
Consulting Fees:  Acorda Therapeutics, Bayer, Biogen, Inc., EMD Serono, Genentech, Genzyme, Novartis, Teva Pharmaceutical Industries, TG Therapeutics, Inc.; Contracted Research: Acorda Therapeutics, Biogen, Inc., Chugai Pharma USA, Inc., EMD Serono, Genentech, Novartis, Ono Pharma USA, Inc., Teva Pharmaceutical Industries, TG Therapeutics, Inc.

Lori Mayer, DNP, MSN, RN, MSCN
Consulting Fees (e.g. advisory boards):  Biogen, Inc., EMD Serono, Genentech, Novartis, Sanofi Genzyme; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g. speakers’ bureaus): Biogen, Inc., EMD Serono, Novartis, Sanofi Genzyme.

The following CMEology planners and managers, Rob Lowney, Dannielle McGuire, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please contact Postgraduate Institute for Medicine at: (303) 799-1930 or inquiries@pimed.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Postgraduate Institute for Medicine
Evidence-Based Diagnosis & Management of Multiple Sclerosis

Evidence-Based Diagnosis & Management of Multiple Sclerosis

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit
0.5 ANCC Contact Hour
Released: June 28, 2018
Expires: June 27, 2019
30 minutes to complete

Target Audience

Neurology clinicians, including physicians, nurse practitioners, physician assistants, and neurology nurses

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize and diagnose the spectrum of multiple sclerosis (MS), from clinically isolated syndrome (CIS) to the various forms of MS (relapsing-remitting and progressive forms), using established, updated, clinical imaging and laboratory criteria 
  2. Appropriately use available and emerging disease-modifying therapies (DMTs) for MS based on their efficacy, safety, and tolerability profiles, as well as their approved or anticipated indications for the various forms of MS
  3. Recognize and manage treatment failure, including switching DMTs
  4. Monitor disease and patient outcomes, including patient adherence, according to recommended protocols 
  5. Use shared decision making when prescribing DMTs to improve treatment adherence and patient outcomes

Jointly Provided By


This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Patricia K. Coyle, MD, FAAN, FANA
Professor & Vice Chair (Clinical Affairs)
  Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Patricia K. Coyle, MD, FAAN, FANA, has affiliations with Accordant, Acorda Therapeutics, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, and Serono (Consulting); Actelion, Genentech/Roche, MedDay, NINDS, and Novartis (Contracted Research).

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s). Designated for 0.5 contact hour(s) of pharmacotherapy credit for Advanced Practice Registered Nurses.

How to Receive Credit

Physicians, nurse practitioners, registered nurses, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Biogen, Genentech, and Novartis Pharmaceuticals Corporation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME / CNE
Global Education Group
Multiple sclerosis management: Key clinical take home points from the AAN Annual Meeting

Multiple sclerosis management: Key clinical take home points from the AAN Annual Meeting

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 Contact Hour(s)
Released: June 20, 2018
Expires: June 1, 2019
45 minutes to complete

Accredited By

Global Education Group

Joint Providership Statement

  
This activity is jointly provided by Global Education Group and Strategic Consultants International.

Fee Information

There is no fee for participating in this educational activity.

Target Audience

Neurology physicians, NPs, PAs, and MS Nurses who are interested in the latest insights on the management of patients with multiple sclerosis.

Learning Objectives

At the conclusion of one or more of the proposed activities, participants will be better able to:

  • Describe the recently presented data on the treatment of relapsing remitting and progressive forms of multiple sclerosis (MS)
  • Explain how current management of patients with MS may be adapted to reflect the latest advances.

Activity Description

A series of four faculty video discussions. Each video highlights a different aspect of MS disease management

Statement of Educational Need

Management of MS has advanced dramatically over recent years, with new DMTs becoming available and increasingly, a recognition that ‘NEDA’ is a potential goal of therapy.  As these concepts continue to emerge it is essential that neurologists and MS nurses (and other healthcare providers) caring for patients with MS are fully apprised of recent data.

Importantly, in addition to the actual evidence, clinical interpretation of this information is vital.  To facilitate this, expert insight is necessary to provide a framework for consideration of if/how to amend management approaches in the light of new data and evidence, to improve knowledge and competence, and ultimately, patient care.

Agenda

This activity comprises four individual video discussions. These may be accessed sequentially or as preferred.

Chapter 1. Current and ‘near future’ platform therapies for RRMS
Chapter 2. Highly active injectable DMTs (monoclonal antibodies) in RMS: New data
Chapter 3. Progressive MS
Chapter 4. MS outcomes and predictors of progression

Evaluation and post-test

Faculty

Patricia Coyle, MD
Vice Chair, Department of Neurology, Director, MS Comprehensive Care Center,
Stony Brook University Hospital, East Setauket, New York


Stephen Krieger, MD
Associate Professor of Neurology, Corinne Goldsmith Dickinson Center for MS
Director, Neurology Residency Program, Icahn School of Medicine at Mount Sinai, New York


Gabriel Pardo, MD
Director, OMRF Multiple Sclerosis Center of Excellence
Associate Member, Arthritis & Clinical Immunology Research Program
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma


Jerry Wolinsky, MD
Emeritus Professor in Neurology
McGovern Medical School, part of UTHealth
The University of Texas Health Science Center at Houston, Houston, Texas


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Patricia Coyle, MD
Consultant/Independent Contractor:
Accordant, Acorda, Bayer, Biogen, Celgene, EMD Serono, Genentech/Roche, Novartis, Sanofi-Genzyme
Grant/Research Support:
Actelion, Genentech/Roche, MedDay, Novartis

Stephen Krieger, MD
Consultant/Independent Contractor:
Acorda, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Mallincrodt, Novartis, Teva, TG therapeutic

Gabriel Pardo, MD
Consultant/Independent Contractor:
Biogen, EMD Serono, Genentech, Genzyme, Novartis, Teva

Jerry Wolinsky, MD
Consultant/Independent Contractor:
AbbVie, Actelion, Biogen, Celgene, Clene Nanomedicine, EMD Serono, Forward Pharma A/S, GeNeuro, Genentech/Roche, McDonnel Boehnen Hulbert & Berghoff, MedDay Pharmaceuticals, Novartis Pharmaceuticals, Otsuka, PTC Therapeutics, Sanofi-Genzyme
Honorarium:
AcademicCME, ACTRIMS, Alkermes, CMSC, ECTRIMS, France Foundation, Masters MS (Annenberg Center for Health Sciences at Eisenhower), PlatformQ Health Education, PRIME, Strategic Consultants International, Society for Clinical Trials, WebMD
Royalty:
For out licensed monoclonal antibodies through UTHealth to Millipore (Chemicon International) Corporation

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvasnky
Nothing to disclose

Ashley Marostica
Nothing to disclose

Liddy Knight
Nothing to disclose

Ian Morgan
Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Strategic Consultants International (SCI). Global is accredited by the ACCME to provide continuing medical education for physicians.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation .

Designation of Credit

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation
This educational activity for 0.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must review the materials, complete the post-activity test with a pass mark of 65% or greater and complete the evaluation and credit request.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Strategic Consultants International (SCI) do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: TBD
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Discuss recent developments in the diagnosis of AD such as the role of beta-amyloid and tau biomarkers
  2. Implement shared decision making with the patient and caregiver to develop individualized approach to diagnosis and treatment to improve the quality of life for patients with AD

Activity Description

In this module of a Four-Part Expert Interview Series, Dr. Barry W. Rovner, along with Dr. Richard S. Isaacson, course chair, will provide learners with an update regarding beta-amyloid and tau biomarkers and their role in Alzheimer’s disease (AD) pathology and progression. Recent guidelines and trial data relating to beta-amyloid and tau will be reviewed, and clinical relevance debated. Drs. Rovner and Isaacson will also discuss the diagnostic criteria for Alzheimer’s disease and intervention techniques for the various stages of disease. Upon completion of this educational activity, learners will be better equipped with best practices for managing beta amyloid and tau levels in practice to provide optimal care for patients with AD.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of AD patients, including beta-amyloid and tau biomarkers.

Agenda

The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Barry W. Rovner, MD

Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Jefferson Hospital for Neuroscience
Philadelphia, Pennsylvania


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Barry W. Rovner, MD
Nothing to disclose.

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Review the pathology of Alzheimer’s disease, including disease monitoring and specific biomarkers for early diagnosis
  2. Identify the assessment and testing strategies for early diagnosis, monitoring, and personalized treatment of AD

Activity Description

In this module of a Four-Part Expert Interview Series, Max Lugavere, along with Dr. Richard S. Isaacson, course chair, will explore non-pharmacological approaches to managing patients with Alzheimer’s disease (AD). Multi-modal intervention factors, including nutrition exercise, sleep hygiene and continued education, among others, will be reviewed, and best practices relayed. The faculty will also highlight recent clinical trial data regarding non-pharmacological methods of AD patient care. Clinical relevance of said data, both now and in the pipeline, will be deliberated. Following this educational activity, learners will have a better grasp of non-pharmacological intervention techniques as well as their potential impact in current and forthcoming AD patient care.

Statement of Educational Need

Health care team members need to understand the pathology of Alzheimer’s disease in order to treat it most effectively, including the biomarkers for early diagnosis.

Agenda

Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
James E. Galvin, MD, MPH

Professor and Associate Dean for Clinical Research
Director, Comprehensive Center for Brain Health
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
James E. Galvin, MD, MPH
Nothing to disclose.

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
Non-Pharmacological Approaches to Managing Patients With Alzheimer’s Disease

Non-Pharmacological Approaches to Managing Patients With Alzheimer’s Disease

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: TBD
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Evaluate non-pharmacological approaches for the treatment of AD
  2. Apply evidence-based data of non-pharmacological approaches to develop patient centered care

Activity Description

In this module of a Four-Part Expert Interview Series, Max Lugavere, along with Dr. Richard S. Isaacson, course chair, will explore non-pharmacological approaches to managing patients with Alzheimer’s disease (AD). Multi-modal intervention factors, including nutrition exercise, sleep hygiene and continued education, among others, will be reviewed, and best practices relayed. The faculty will also highlight recent clinical trial data regarding non-pharmacological methods of AD patient care. Clinical relevance of said data, both now and in the pipeline, will be deliberated. Following this educational activity, learners will have a better grasp of non-pharmacological intervention techniques as well as their potential impact in current and forthcoming AD patient care.

Statement of Educational Need

Health care team members need to manage all aspects of Alzheimer’s disease, including non-pharmacological, and understand how these factors affect the AD patient.

Agenda

Non-Pharmacological Approaches to Managing Patients With Alzheimer’s Disease

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Max Lugavere

Health and Science Journalist and Filmmaker
New York, New York


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Max Lugavere
Nothing to disclose.

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD
  2. Implement shared decision making with the multidisciplinary team and patients/caregivers to develop individualized treatment plans and referral to clinical studies to advance treatment and improve the quality of life for patients with AD

Activity Description

In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern day. Emerging therapies for the treatment and management of Alzheimer’s disease will also be assessed. Through completing this educational activity, learners will be better acquainted with emerging and emerged clinical trial data as it relates to AD care.

Statement of Educational Need

Health care team members need to be up-to-date on the most current strategies to delay disease progression in Alzheimer’s patients.

Agenda

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Marc E. Agronin, MD

Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Marc E. Agronin, MD
Consultant/Advisor: Eli Lilly and Company
Speaker's Bureau: Allergan

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Postgraduate Institute for Medicine
Treatment Decision Making and Achieving Therapeutic Goals in Multiple Sclerosis: Individual and Systems-Level Advances: Current Views of the Pathophysiology and Immunopathogenesis of MS

Treatment Decision Making and Achieving Therapeutic Goals in Multiple Sclerosis: Individual and Systems-Level Advances: Current Views of the Pathophysiology and Immunopathogenesis of MS

Start

Faculty

Edward Fox, MD, PhD
Clinical Associate Professor
Department of Neurology
University of Texas Dell Medical School
Austin, TX

Director, Multiple Sclerosis Clinic
Central Texas Neurology Consultants
Round Rock, TX


Lori Mayer, DNP, MSN, RN, MSCN
Director, Medical Research, MS Clinic of Central Texas
Central Texas Neurology Consultants
Round Rock, TX


Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and CMEology

    

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: September 12, 2017
Expires: September 12, 2018
30 minutes to complete

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

Activity Description

In this activity, experts in multiple sclerosis will discuss current views of the pathophysiology and immunopathogenesis of multiple sclerosis.

Statement of Educational Need

The increasing understanding of the immunopathogenesis of MS and the greater availability of disease-modifying therapies (DMTs) have shifted the aims of treatment. Modification of therapies is increasingly common in the context of growing knowledge of MS pathophysiology and DMT mechanisms of action. Education is needed to reformulate treatment strategies on the individual and systems levels.

Goals (Purpose) of Program

Healthcare providers who complete this activity should be able to effectively communicate and foster understanding of the disease process and the mechanism of action of DMTs with their patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the role of B and T cells in MS pathophysiology
  • Identify mechanisms of action of current and emerging disease-modifying therapies in MS

Target Audience

This certified activity is designed to address the educational needs of neurologists, neurology advanced practice clinicians, and other healthcare providers who care for patients with multiple sclerosis.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, the certificate will be made available immediately.

Media

Internet activity

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty have disclosed the following:
Edward Fox, MD, PhD
Consulting Fees:  Acorda Therapeutics, Bayer, Biogen, Inc., EMD Serono, Genentech, Genzyme, Novartis, Teva Pharmaceutical Industries, TG Therapeutics, Inc.; Contracted Research: Acorda Therapeutics, Biogen, Inc., Chugai Pharma USA, Inc., EMD Serono, Genentech, Novartis, Ono Pharma USA, Inc., Teva Pharmaceutical Industries, TG Therapeutics, Inc.

Lori Mayer, DNP, MSN, RN, MSCN
Consulting Fees (e.g. advisory boards):  Biogen, Inc., EMD Serono, Genentech, Novartis, Sanofi Genzyme; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g. speakers’ bureaus): Biogen, Inc., EMD Serono, Novartis, Sanofi Genzyme.

The following CMEology planners and managers, Rob Lowney, Dannielle McGuire, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please contact Postgraduate Institute for Medicine at: (303) 799-1930 or inquiries@pimed.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.